Large surface area microparticles cancer therapeutic platform designed for extended release at tumor site; direct tumor kill, immune response, and minimal side effects
Employees: 1-10
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Tenzing Ca... | tenzing.vc |
Mentions in press and media 5
| Date | Title | Description |
| 26.02.2026 | NanOlogy, LLC CEO David J. Arthur Discusses Their PURCISION™ Technology Advancing Intratumoral Therapy to Treat Cancer | David J. Arthur, CEO, NanOlogy, LLC CEOCFO interviews NanOlogy, LLC CEO David J. Arthur on Solving Toxicity & Bioavailability Problems when Treating Cancer NanOlogy is a leader in Intratumoral (IT) Therapy establishing feasibility of th... |
| 07.03.2023 | NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer | NanOlogy LLC, a clinical-stage oncology company, announced issuance of a US patent titled: Local Delivery of Antineoplastic Particles in Combination with Systemic Delivery of Immunotherapeutic Agents for the Treatment of Cancer. The patent ... |
| 03.05.2022 | Andera Partners supports Tubulis in a €60 million Series B financing to accelerate the development of its ADCs | Andera Partners, a leading European private equity player, through its biotech and medtech practice Andera Life Sciences, announced today that it is leading a €60 million (USD $63 million) Series B financing round for Tubulis with participa... |
| 25.07.2019 | Does the WRI’s new Sustainable Food Future report need an update already? | In the southern Polish city of Katowice last December, news coverage of the UN’s COP 24 meeting on climate change suddenly and dramatically surged, mostly thanks to a three-minute speech given by a Swedish teen activist with Asperger’s synd... |
| 31.05.2017 | Merck Ventures leads $11M round in solid tumor startup | Merck Ventures has led a $10.8 million (€9.6 million) investment in Inthera Bioscience. The series A sets the Swiss biotech up to wrap up preclinical development of a lead candidate against cancers associated with human papillomavirus (HPV)... |